Study of BROdalumab in Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is a rare liver disease. In people with PSC, the body's immune system mistakenly attacks the bile ducts, causing swelling and scarring. Over time, this can lead to liver damage. Currently, there are no approved medicines that stop PSC from progressing. This trial is testing a medicine called brodalumab. Brodalumab is already safely used to treat a skin condition called psoriasis. It works by blocking a specific protein that drives inflammation in the body. Doctors at NHS hospitals in Norwich, Oxford, Cambridge, and Birmingham want to find out if brodalumab is safe and easy to take for people with PSC. Participants will use an injection pen to take the medicine for 12 weeks. The findings will help researchers decide if brodalumab should be tested in a larger clinical trial to help future patients.
At a glance
What is this study about?
Primary sclerosing cholangitis (PSC) is an uncommon condition affecting the liver and bile ducts. Bile ducts are the small tubes that carry digestive fluid from the liver to the gut. In PSC, the body's defence system mistakenly causes inflammation in these tubes, leading to scarring, narrowing, and potential liver damage. At present, there are no medications that cure PSC or slow down its progression, meaning some people eventually need a liver transplant.
Recent scientific studies show that certain white blood cells release an inflammatory chemical called IL-17, which harms the bile ducts. Brodalumab is a targeted treatment that blocks IL-17. It is already used safely to calm down inflammation in people with severe psoriasis. Because PSC involves similar immune signals, scientists believe brodalumab might also help reduce inflammation in the liver.
This pilot study is an essential first step. Before doctors can test the medicine in a very large group of people, they need to check how well patients tolerate it, whether it causes any side effects, and how it fits into daily life. The goal is to collect vital safety information that could pave the way for a brand-new treatment for PSC.
Key takeaways
- Tests whether a psoriasis medicine called brodalumab is safe and helpful for primary sclerosing cholangitis (PSC).
- Open to adults aged 18 to 75 with PSC, including those with quiet or mild bowel disease.
- Involves self-injecting the medicine at home for 12 weeks after full training.
- Requires regular clinic visits for blood tests, liver scans, and bowel checks.
- Takes place at NHS centres in Norwich, Oxford, Cambridge, and Birmingham.
Who may be eligible?
This trial is open to adults aged between 18 and 75 who have a confirmed diagnosis of 'large-duct' PSC. Doctors usually confirm this diagnosis using routine liver blood tests and special magnetic resonance (MRCP) scans of the bile ducts.
Many people living with PSC also have inflammatory bowel disease (IBD), such as ulcerative colitis or Crohn's disease. You may still be able to join if you have IBD, but your bowel symptoms must currently be quiet (in remission) or very mild. The study team will check your recent bowel tests to make sure it is safe for you to take part.
To join, you must be able to attend appointments at one of the four study centres in Norwich, Oxford, Cambridge, or Birmingham, and feel comfortable giving your written consent.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am between 18 and 75 years of age.
- I have an established diagnosis of large-duct PSC.
- If I have colitis or Crohn's disease, it is currently quiet or mild.
- I can travel to hospital appointments in Norwich, Oxford, Cambridge, or Birmingham.
- I am willing to learn how to do a simple self-injection at home.
What does participation involve?
Taking part in this study lasts around three to four months. You will receive the study medicine, brodalumab, for a total of 12 weeks. The drug comes in a pre-filled injection pen. A study nurse will show you how to use the pen so that you can easily do the injections yourself at home. You will take one injection each week for the first three weeks, and then one injection every two weeks after that.
During the trial, you will visit your hospital clinic for regular check-ups. These visits will involve standard blood tests, simple liver scans, and completing short questionnaires about your health and quality of life. You will also have a camera test of the bowel (colonoscopy) so doctors can check the health of your gut lining. The trial team will stay in regular contact to support you and answer any questions.
Potential risks and benefits
Locations (4)
- Norfolk and Norwich University Hospitals NHS Foundation TrustCity onlyNorwich, England
- Oxford University Hospitals NHS Foundation TrustCity onlyOxford, England
- Queen Elizabeth HospitalApproximateBirmingham, England
- Nottingham University Hospitals NHS Trust - Queen's Medical Centre CampusCity onlyNottingham, England
Common questions
How do I take the study medicine?
You take brodalumab using a simple, pre-filled injection pen under the skin. The hospital team will provide full training so you feel confident doing it at home.
Can I join if I have Crohn's disease or ulcerative colitis?
Yes, but your bowel disease must be quiet or very mild. The doctors will check your recent medical records and bowel tests to ensure it is safe.
Where does the study take place?
The trial is run at four major NHS hospital centres in Norwich, Oxford, Cambridge, and Birmingham. You can choose the centre closest to you.
Do I have to pay to take part?
No, clinical trials on the NHS are free. The study team can often help cover reasonable travel costs to and from your clinic visits.
What happens if I change my mind during the study?
You can leave the study at any time without giving a reason. Your standard medical care and your relationship with your doctors will stay exactly the same.
How to find out more
Amera Elzubeir
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.